Sign up to save your podcasts
Or
Share The Barometer Global Survey
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
The Barometer Global Survey
In this special episode, I am joined by my friend and fellow Barometer Program member, Professor Focke Ziemssen, Director of the University Eye Clinic at the University Hospital Leipzig, Germany.
Join us as we discuss the findings of the Barometer Global Survey, a worldwide study capturing the experiences of patients with neovascular age-related macular degeneration, diabetic retinopathy, and diabetic macular edema, as well as their healthcare teams. In this episode, Focke and I unpack the results of the survey and their implications. We also discuss potential solutions that we could apply in our practices to help improve the experiences of our patients.
To further explore the findings of the Barometer Global Survey, read the publications reporting the results for neovascular age-related macular degeneration and diabetic macular edema that were discussed during this episode. Insights from the surveys were transformed into evidence-based educational resources for patients and healthcare providers by the Barometer Program - find them on the AMD Barometer Website.
If you enjoyed this episode, SUBSCRIBE to “A Chat with Anat” to make sure you never miss an episode!
Speaker disclosures:
Professor Anat Loewenstein
Consultant: 4DMT, Abbvie, Astellas, Aviceda, Bayer, Beyeonics, Boehringer Ingelheim; Eyepoint, NotalVision, Ocular Therapeutix, Oculis, Ocuphire, Opthea, Roche, and Voiant.
Professor Focke Ziemssen
Travel grants and personal fees: Allergan/AbbVie, Alimera, Bayer Healthcare, Biogen, Boehringer Ingelheim, Clearside, Janssen, Novartis, Novo Nordisk, Merck, Sharp & Dohme, Regeneron, Roche/Genentech, Sanofi, Sandoz, and Stada.
April 2026 | PP-PF-OPHT-ALL-0263-1
This podcast series is intended for HCPs, and is not intended for UK audiences.
Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing.
This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise.
The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer. The activities of the Barometer Program are funded and facilitated by Bayer where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program.
The Vision Academy is a group of over 80 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer.
View all episodes
By ApotheComIn this special episode, I am joined by my friend and fellow Barometer Program member, Professor Focke Ziemssen, Director of the University Eye Clinic at the University Hospital Leipzig, Germany.
Join us as we discuss the findings of the Barometer Global Survey, a worldwide study capturing the experiences of patients with neovascular age-related macular degeneration, diabetic retinopathy, and diabetic macular edema, as well as their healthcare teams. In this episode, Focke and I unpack the results of the survey and their implications. We also discuss potential solutions that we could apply in our practices to help improve the experiences of our patients.
To further explore the findings of the Barometer Global Survey, read the publications reporting the results for neovascular age-related macular degeneration and diabetic macular edema that were discussed during this episode. Insights from the surveys were transformed into evidence-based educational resources for patients and healthcare providers by the Barometer Program - find them on the AMD Barometer Website.
If you enjoyed this episode, SUBSCRIBE to “A Chat with Anat” to make sure you never miss an episode!
Speaker disclosures:
Professor Anat Loewenstein
Consultant: 4DMT, Abbvie, Astellas, Aviceda, Bayer, Beyeonics, Boehringer Ingelheim; Eyepoint, NotalVision, Ocular Therapeutix, Oculis, Ocuphire, Opthea, Roche, and Voiant.
Professor Focke Ziemssen
Travel grants and personal fees: Allergan/AbbVie, Alimera, Bayer Healthcare, Biogen, Boehringer Ingelheim, Clearside, Janssen, Novartis, Novo Nordisk, Merck, Sharp & Dohme, Regeneron, Roche/Genentech, Sanofi, Sandoz, and Stada.
April 2026 | PP-PF-OPHT-ALL-0263-1
This podcast series is intended for HCPs, and is not intended for UK audiences.
Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing.
This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise.
The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer. The activities of the Barometer Program are funded and facilitated by Bayer where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program.
The Vision Academy is a group of over 80 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer.